Immunology: Current Research

Commentary Open Access

Prognostic Biomarkers for COVID-19 Patients: Inhibitory Immune Checkpoint Receptors and Ligands

Hania Szajewska*

Department of Paediatrics, The Medical University of Warsaw, Warsaw, Poland

Commentary

Coronavirus disease 2019 (COVID-19) is caused by *SARS-CoV-2*. Throughout T-cell activation, the system uses totally different stop pathways to keep up co-inhibitory and co-stimulatory signals. In COVID-19, expression of immune checkpoints (ICs) is one in all the foremost necessary manifestations, additionally to lymphopenia and inflammatory cytokines, contributive to worse clinical outcomes. There's an argument whether or not up regulation of ICs in COVID-19 patients may cause T-cell exhaustion or activation. This review summarizes the on the available studies that investigated IC receptors and ligands in COVID-19 patients, still as their impact on T-cell operate. Many IC receptors and ligands, as well as CTLA-4, BTLA, TIM-3, VISTA, LAG-3, TIGIT, PD-1, CD160, 2B4, NKG2A, Galectin-9, Galectin-3, PD-L1, PD-L2, LSECtin, and CD112, were up regulated in COVID-19 patients. Supported the on the available studies, there's a potential relationship between malady severity and magnified expression of IC receptors and ligands. Overall, the up regulation of some ICs can be used as a prognostic biomarker for disease severity.

Coronavirus disease 2019 (COVID-19) may be a pandemic disease from December 2019. Since the initial wave of cases appeared in Wuhan, China, over 260 million people worldwide are infected with COVID-19, leading to concerning six million deaths until now [1]. Most infected patients square measure with none symptoms or have delicate symptoms, however some patients become severely unwell and wish to be admitted to the hospitals. This surprising happening has highlighted the need to develop new vaccinations and totally different therapies to combat COVID-19. Significantly, there square measure new approved direct antiviral medications for COVID-19 patients. For example, remdesivir, a glycoside analog, is incorporated into the *SARS-CoV-2* infectious agent polymer-dependent RNA enzyme (RdRp) complicated and prevents its translocation. The North American country Food and Drug Administration (FDA) has licensed it for the treatment of hospitalized COVID-19 patients. What is more, molnupiravir, a glycoside analogue, is that the initial orally taken direct-acting medicament that has been shown to be effective within the demolition of infectious agent polymer, whereas maintaining high safety and tolerability profiles [2].

Lymphopenia is a general characteristic of many respiratory viral diseases such as human rhinovirus and influenza. COVID-19-associated lymphopenia can be a lot of severe and protracted, compared with alternative metabolic process infections. Though lymphopenia isn't absolutely understood in COVID-19, the decline in T-cell numbers may be a common symptom among patients with severe diseases. Recent studies showed a decline within the total range of T cells, still as a negative relationship between T-cell depletion and prognosis, notably in COVID-19 who arrive at the hospital with low CD4+ and CD8+ T cell numbers, which may cause worse clinical outcomes. Clearly, these patients ought to be monitored for any changes in levels of T cells. In severe cases of COVID-19, it's been shown that CD8+ T cells and natural killer (NK) cells were reduced in numbers, however they were active. The quantity and immunologic standing of GrA+CD8+ T cells and NK cells were recovered when the patients' condition improved. Consistent with this study, perforin+ NK cells and GrA+CD8+ T cells can be helpful for the identification of COVID-19 patients. Memory T cells square measure basically necessary to fight against *SARS-CoV-2* reinfection and to work out the period of vaccinum protection [3].

Some of T-cell repressing receptors seem to be co-expressed throughout exhausted T-cell differentiation. Apparently, Yang et al. showed that PD-1 binds to the TIM-3 substance Gal-9, that attenuates Gal-9/TIM-3-induced necrobiosis. Moreover, Baitsch et al. found that naive T cells square measure primarily controlled by BTLA and TIM-3 receptors, whereas effector cells move *via* larger amounts of repressing receptors [4].

Binding of IC receptors with their ligands suppresses T-cell activity and performance, serving to within the regulation of immunity. Infectious agent infections induce the overexpression of some IC ligands in numerous immune cells, leading to a decrease of the infectious agent clearance and magnified mortality. Herein, we have a tendency to gift the few on the market studies that investigated IC ligands in COVID-19 patients.

COVID-19 may be a pandemic disease that's impacting people everywhere the world. The severity of the disease is set by the signs and symptoms that people exhibit [5]. AN increased expression of immune stop molecules may result in stimulation of the cell death of T cells, decline within the range of T cells, and lymphopenia. Some studies reportable a relationship between up regulation of IC receptors on T cells and also the severity of COVID-19. Specifically, once immune cells square measure over activated, ICs square measure up regulated and inflammatory cytokines square measure created in excessive amounts that increase the disease severity. Therefore, IC overexpression in COVID-19 patients may not flow from to T-cell exhaustion with impaired antiviral responses. Some studies found that the overexpression of IC receptors on T cells could modulate the response and defend important organs from an excessive inflammatory response in severe COVID-19 patients.

Few studies have investigated the expression level of IC ligands in COVID-19 patients. Supported the few on the available studies, there's a relationship between disease severity and magnified expression of IC ligands. However, there aren't any on the market studies investigation the expression levels of some IC ligands as well as B7-H4, B7-H5, and

***Corresponding author:** Hania Szajewska, Department of Paediatrics, The Medical University of Warsaw, Warsaw, Poland, E-mail: hanias@gmail.com

Received: 13-Apr-2022, Manuscript No. icr-22-60737; **Editor assigned:** 15-Apr-2022, PreQC No. icr-22-60737 (PQ); **Reviewed:** 29-Apr-2022, QC No. icr-22-60737; **Revised:** 04-may-2022, Manuscript No. icr-22-60737 (R); **Published:** 11-May-2022, DOI: 10.4172/icr.1000119

Citation: Szajewska H (2022) Prognostic Biomarkers for COVID-19 Patients: Inhibitory Immune Checkpoint Receptors and Ligands. Immunol Curr Res, 6: 119.

B7-H6 in COVID-19 patients, and it'd be fascinating to try and do that.

Most of the on the market studies on COVID-19 patients World Health Organization have undertaken ICI square measure focused on PD-1 inhibition. Alternative ICIs during this setting ought to be studied still. More studies are needed to evaluate the safety of ICI in cancer and non-cancer COVID-19 patients.

Acknowledgement

None

Conflict of Interest

None

References

1. Pu D, Yin L, Zhou Y, Li W, Huang L, et al. (2020) Safety and efficacy of immune checkpoint inhibitors in patients with HBV/HCV infection and advanced-stage cancer: a systematic review. Medicine (Baltimore) 99: e19013.
2. Wen X, Wang Y, Ding Y, Li D, Li J, et al. (2016) Safety of immune checkpoint inhibitors in Chinese patients with melanoma. Melanoma Res 26:284-289.
3. Wykes MN, Lewin SR (2018) Immune checkpoint blockade in infectious diseases. Nat Rev Immunol 18: 91-104.
4. Keir ME, Butte MJ, Freeman GJ, Arlene H Sharpe (2008) PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26:677-704.
5. Dougall WC, Kurtulus S, Smyth MJ, Anderson AC (2017) TIGIT CD96: new checkpoint receptor targets for cancer immunotherapy. Immunol Rev 276:112-120.